GABA transporters (GAT-1) in Alzheimer's disease

Journal of Neural Transmission

Volumn 106, Issue 11-12, 1999, Pages 1141-1149

  Nagga K ^a   Bogdanovic, N ^b   Marcusson, J ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b NONE

Author keywords

Alzheimer's disease; GABA transporters; GAT 1

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; RADIOLIGAND; TIAGABINE;

4 AMINOBUTYRIC ACID UPTAKE; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GABAERGIC SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN CHEMISTRY; CARRIER PROTEINS; CAUDATE NUCLEUS; FEMALE; FRONTAL LOBE; GABA AGONISTS; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; NEURITES; NIPECOTIC ACIDS; ORGANIC ANION TRANSPORTERS; TEMPORAL LOBE; TRITIUM;

EID: 0343048399     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050230     Document Type: Article

References (47)

1. Arai H, Kobayashi K, Ichimiya Y, Kosaka K, Iizuka R (1984) A preliminary study of free amino acids in the postmortem temporal cortex from Alzheimer-type dementia patients. Neurobiol Aging 5: 319-321
2. Bennett ER, Kanner BI (1997) The membrane topology of GAT-1, a (Na++Cl-)- coupled gamma-aminobutyric acid transporter from rat brain. J Biol Chem 272(2): 1203-1210
3. Bogdanovic N, Morris JH (1995) Diagnostic criteria for Alzheimer's disease in multi-centre brain banking. In: Cruz-Sanchez FF, Ravid R, Cuzner ML (eds) Neuropathological diagnostic criteria for brain banking. IOS Press, Amsterdam, pp 20-29
4. Bonanno G, Ruelle A, Andrioli GC, Raiteri M (1991) Cholinergic nerve terminals of human cerebral cortex possess a GABA transporter whose activation induces release of acetylcholine. Brain Res 539(2): 191-195
5. Borden LA (1996) GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 29(4): 335-356
6. Borden LA, Dhar TGM, Smith KE, Weinshank RL, Branchek TA, Gluchowski C (1994) Tiagabine, SK&F 89976-A, CI-966 and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 269(2): 219-224
7. Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxemia in senile dementia and other atrophies. Brain 99: 459-496
8. Braak E, Braak H (1997a) Alzheimer's disease: transiently developing dendritic changes in pyramidal cells of sector CA1 of the Ammon's horn. Acta Neuropathol (Berl) 93(4): 323-325
9. Braak H, Braak E (1997b) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18(4): 351-357
10. Braestrup C, Nielsen EB, Sonnewald U, Knutsen LJS, Andersen KE, Jansen JA, Frederiksen K, Andersen PH, Mortensen A, Suzdak PD (1990) (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-3n-l-yl]nipecotic acid binds with high affinity to the brain γ-aminobutyric acid uptake carrier. J Neurochem 54: 639-647
11. Brodie MJ (1995) Tiagabine pharmacology in profile. Epilepsia 36: S7-S9
12. Cross AJ, Slater P, Candy JM, Perry EK, Perry RH (1987) Glutamate deficits in Alzheimer's disease. J Neurol Neurosurg Psychiatry 50: 357-358
13. 3H]Nipecotic acid binding to γ-aminobutyric acid uptake sites in postmortem human brain. J Neurochem 55: 165-168
14. DeFelipe J, Gonzalez-Albo MC (1998) Chandelier cell axons are immunoreactive for GAT-1 in the human neocortex. Neuroreport 9(3): 467-470
15. Dewar D, McCulloch J (1994) Abnormalities in non-cholinergic neurotransmitter systems in Alzheimer's disease. In: Burns A, Levy R (eds) Dementia. Chapman & Hall, London, pp 159-183
16. Durkin MM, Smith KE, Borden A, Weinshank RL, Branchek TA, Gustafson EL (1995) Localization of messenger RNAs encoding three GABA transporters in rat brain: an in situ hybridization study. Brain Res Mol Brain Res 33(1): 7-21
17. Enna SJ (1981) GABA receptor pharmacology: functional considerations. Biochem Pharmacol 30: 907-913
18. Francis PT, Cross AJ, Bowen DM (1994) Neurotransmitters and neuropeptides. In: Terry RD, Katzman R, Bick KL (eds) Alzheimer's disease. Raven Press, New York, pp 247-261
19. Goldman J, Côté L (1991) Aging of the brain: dementia of the Alzheimer's type. In: Kandel ER, Schwartz JH, Jessell TM (eds) Principles of neural science. Prentice Hall, London, pp 974-983
20. Griffiths PD, Perry RH, Crossman AR (1994) A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett 169: 68-72
21. Halonen T, Nissinen J, Jansen JA, Pitkänen A (1996) Tiagabine prevents seizure, neuronal damage and memory impairment in experimental status epilepticus. Eur J Pharmacol 299: 69-81
22. Hardy JA, Barton A, Lofdahl E, Cheetham SC, Johnston GAR, Dodd PR (1986) Uptake of γ-aminobutyric acid and glycine by synaptosomes from postmortem human brain. J Neurochem 47: 460-467
23. Hardy J, Cowburn R, Barton A, Reynolds G, Dodd P, Wester P, O'Carroll AM, Lofdahl E, Winblad B (1987) A disorder of cortical GABAergic innervation in Alzheimer' disease. Neurosci Lett 73: 192-196
24. Hauser W, Morris ML, Heston LL, Anderson VE (1986) Seizures and myoclonus in patients with Alzheimer's disease. Neurology 36: 1226-1230
25. Krogsgaard-Larsen P (1988) GABA synaptic mechanisms: stereochemical and conformational requirements. Med Res Rev 8: 27
26. Krogsgaaard-Larsen P, Johnston GAR (1975) Inhibition of GABA uptake in rat brain slices by nipecotic acid, various isoxazoles and related compounds. J Neurochem 25: 797-802
27. 3H]Nipecotic acid: identification of GABA uptake sites in frozen tissue. In: Okada Y, Roberts E (eds) Problems in GABA research. Excerpta Medica, Amsterdam, pp 355-365
28. Matsumoto RR (1989) GABA receptors: are cellular differences reflected in function? Brain Res Rev 14: 203-225
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34: 939-944
30. McGeer P, McGeer EG (1976) Enzymes associated with the metabolism of catecholamines, acetylcholine and GABA in human controls and patients with Parkinson's disease and Huntington's chorea. J Neurochem 26: 65-76
31. Minard FN, Mushawar IK (1966) Synthesis of γ-aminobutyric acid from a pool of glutamic acid in brain after decapitation. Life Sci 5: 1409-1413
32. Minelli A, Brecha NC, Karschin C, DeBiasi S, Conti F (1995) GAT-1, a high affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex. J Neurosci 15(11): 7734-7746
33. Mirra SS, Heyman A, McKeel D (1991) The consortium to establish a registry for Alzheimer's disease (CERAD), part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486
34. Mizukami K, Ikonomovic MD, Grayson DR, Rubin RT, Warde D, Sheffield R, Hamilton RL, Davies P, Armstrong DM (1997) Immunohistochemical study of GABA(A) receptor beta2/3 subunits in the hippocampal formation of aged brains with Alzheimer-related neuropathological changes. Exp Neurol 147(2): 333-345
35. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C (1991) Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196: 257-266
36. Perry EK (1994) Cholinergic component of cognitive impairment in dementia. In: Burns A, Levy R (eds) Dementia. Chapman & Hall, London, pp 143-157
37. Sasaki H, Muramoto O, Kanazawa I, Arai H, Kosaka K, Iizuka R (1986) Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 19: 263-269
38. Scheel-Krüger J (1986) Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neurol Scand 73: 1-54
39. Simpson MDC, Cross AJ, Slater P, Deakin JFW (1988a) Loss of cortical GABA uptake sites in Alzheimer's disease. J Neural Transm 71: 219-226
40. Simpson MDC, Cross AJ, Slater P, Reynolds GP (1988b) [3H]-Nipecotic acid binding to GABA uptake sites in Huntington's disease. Br J Pharmacol 93: 158P
41. Smith CCT, Bowen DM, Sims NR, Neary D, Davison AN (1983) Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. Brain Res 264: 138-141
42. Spokes EGS, Garrett NJ, Rossor MN, Iversen LL (1980) Distribution of GABA in postmortem brain tissue from control, psychotic, and Huntington's Chorea subjects. J Neurol Sci 48: 303-313
43. Sundman I, Lernmark U, Marcusson J (1992) [3H]Nipecotic acid binding to GABA uptake sites in human brain. Brain Res 580: 311-316
44. Suzdak PD, Jansen JA (1995) A review of the preclinical pharmacology of Tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36: 612-626
45. Suzdak PD, Swedberg MDB, Andersen KE, Knutsen LJS, Braestrup C (1992) In vivo labeling of the central GABA uptake carrier with 3H-Tiagabine. Life Sci 51: 1857-1868
46. Suzdak PD, Foged C, Andersen KE (1994) Quantitative autoradiographic characterization of the binding of [3H]tiagabine (NNC 05-328) to the GABA uptake carrier. Brain Res 647: 231-241
47. Tarbit I, Perry EK, Perry RH, Blessed G, Tomlinson BE (1980) Hippocampal free amino acids in Alzheimer's disease. J Neurochem 35: 1246-1249